The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Refining CLL diagnosis and response monitoring: a future outlook
In this video, Anton Langerak, PhD, Erasmus University, Rotterdam, Netherlands, briefly comments on the future of diagnosis and response monitoring in chronic lymphocytic leukemia (CLL), highlighting the importance of a more integrated approach that combines genetic, proteomic, and other markers to refine diagnosis and prognosis. Prof. Langerak also notes that sensitive monitoring of remissions requires further investigation into the use of circulating cells and cell-free liquid biopsy analyses. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So what I see is a more integrated approach of all kinds of different markers that we can use. Not only genetic markers, but maybe also proteomic profiles that we see more often. So to refine all the information… to refine the diagnosis and prognosis by having all the information together. So that’s on the one hand.
I think on the other end of the spectrum where we aim for more sensitive monitoring, I think what our main challenge is also is to see whether if we use the circulating cells in the blood, if that’s enough for monitoring the remissions or whether we need other materials or in fact other technologies to try and access information from other compartments in the body...
So what I see is a more integrated approach of all kinds of different markers that we can use. Not only genetic markers, but maybe also proteomic profiles that we see more often. So to refine all the information… to refine the diagnosis and prognosis by having all the information together. So that’s on the one hand.
I think on the other end of the spectrum where we aim for more sensitive monitoring, I think what our main challenge is also is to see whether if we use the circulating cells in the blood, if that’s enough for monitoring the remissions or whether we need other materials or in fact other technologies to try and access information from other compartments in the body. So I think especially the cell-free liquid biopsy analyses are going to be very interesting to see how those can contribute to that further monitoring.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research support: Roche, J&J; Speaker fee: J&J; Chair of EuroClonality (EuroClonality receives royalties based on collective IP).
